American Society of Hirudotherapy

Flap infection associated with medicinal leeches in reconstructive surgery: two new drug-resistant organisms

Bibbo C, Fritsche T, Stemper M, Hall M (2013) · Journal of Reconstructive Microsurgery · n=2

RCT evidence detailTrial reference
GRADE Very LowInsufficient evidenceCondition: Venous Congestion in Surgical Flaps →
Sample size of this trial compared with other Venous Congestion in Surgical Flaps trialsHuang D 20221232Valdes CA 2023313Hamzah M 2023225Iaprintsev V 202575Trigonis R 202142McMichael A 202430Engel ER 202422Sonmez E 201120Brandewie K 202410Bibbo C 20132
This trial (highlighted) by sample size alongside other indexed Venous Congestion in Surgical Flaps trials. Larger trials generally carry more statistical weight.

Study Profile

Design
two-case report with management protocol review (Marshfield Clinic, Wisconsin)
Sample size (n)
2
Intervention
Standard leech therapy in reconstructive surgery patients with subsequent identification of two new multidrug-resistant organisms causing flap infection
Comparator
Standard Aeromonas hydrophila-targeted prophylactic regimens (proven inadequate for these strains)
Primary endpoint
Identification of novel resistant organisms and clinical management protocol
Primary result
Two new multidrug-resistant organisms identified from medicinal leech therapy resulting in flap infection; suspected leech-borne infection evaluation and management protocol presented
Follow-up duration
Postoperative infection course
PMID
23599212

Key Findings

  • Two new multidrug-resistant organisms identified
  • Beyond traditional Aeromonas hydrophila coverage
  • Comorbidities: arthropathy, obesity (morbid)
  • Management protocol for suspected leech-borne resistant infections
  • Supports antibiogram-guided empiric therapy

Limitations

  • Only 2 cases - cannot characterize population resistance
  • Single institution experience
  • Specific organisms not detailed in abstract
  • Underlying comorbidities may select for resistant flora
  • Cannot recommend universal protocol changes

Clinical Implications

Bibbo 2013 documents two novel multidrug-resistant organisms from medicinal leech therapy and provides clinical management protocol. For US clinicians under K040187, the case report highlights the need for individualized microbiologic evaluation in suspected leech-borne infections, particularly in patients with significant comorbidities (obesity, joint disease).

Related Trials

Prospective Randomized Pilot Study Comparing Bivalirudin Versus Heparin in Neonatal and Pediatric Extracorporeal Membrane Oxygenation

McMichael A, Weller J, Li X, Hatton L, Zia A, Raman L (2024)

Efficacy of Bivalirudin for Therapeutic Anticoagulation in COVID-19 Patients Requiring ECMO Support

Trigonis R, Smith N, Porter S, Anderson E, Jennings M, Kapoor R, Hage C, Moiz S, Garcia J, Rahman O (2021)

Bivalirudin versus heparin anticoagulation in patients receiving extracorporeal membrane oxygenation

Huang D, Guan Q, Qin J, Shan R, Wu J, Zhang C (2022)

Heparin-based versus bivalirudin-based anticoagulation in pediatric extracorporeal membrane oxygenation: A systematic review

Valdes CA, Sharaf OM, Bleiweis MS, Jacobs JP, Mumtaz M, Sharaf RM, Jeng EI, Peek GJ (2023)

← Back to RCT Library

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.